Abstract
This study aims to develop new molecular structures as potential therapeutic agents against COVID-19, utilizing both in silico and in vitro studies. Potential targets of cepharanthine (CEP) against COVID-19 to reveal its underlying mechanism of action were evaluated using in silico screening experiments. A library of new molecules was docked into the receptor binding domain of the SARS-CoV-2 spike glycoprotein complex with its receptor, human ACE2, to identify promising compounds. Receptor-oriented docking was performed using the most likely macromolecular targets, aimed at inhibiting key viral replication pathways and reducing inflammatory processes in damaged tissues. The hit molecules showed potential inhibition of Mpro and PLpro proteases of SARS-CoV-2, which are involved in viral replication. They also showed a potential inhibitory effect on Janus kinase (Jak3), which mediates intracellular signaling responsible for inflammatory processes.
The in vitro study examined the effects of the selected hit molecules on the generation of superoxide anions and the release of elastase in activated neutrophils, which are factors that exacerbate tissue inflammation and worsen the clinical manifestations of COVID-19. It was demonstrated that 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1,6-dihydropyrimidin-2-yl)thio)-N-(3-methoxyphenyl)acetamide (Hit15) inhibited virus infection by 43.0% at 10 μM using pseudovirus assay and suppressed fMLF/CB-induced superoxide anion generation and elastase release in human neutrophils with IC50 values 1.43 and 1.28 μM, respectively. Hit15 showed promising activity against coronavirus that can be further developed into a therapeutic agent.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Chang Gung Memorial Hospital (Registration number: IRB No.: 202301906A3C501).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
vivanov{at}karazin.ua, (V.V.I.); abzakharov{at}karazin.ua, (A.B.Z.); dmitriy25102002{at}gmail.com, (D.O.A.); sergiy.m.kovalenko{at}karazin.ua, (S.M.K.); lar0858{at}gmail.com, (L.V.Y); onkalugin{at}gmail.com, (O.M.K.) o.mykhailenko{at}nuph.edu.ua; (O.O.M.); vgeor{at}nuph.edu.ua; (V.A.G.) michalk{at}kmu.edu.tw, (M.K.) d1001501{at}cgu.edu.tw (S.-Y.F.), oo66931{at}gmail.com, (Y.-L.C.); htl{at}mail.cgust.edu.tw, (T.-L.H.), mohamed.elshazly{at}pharma.asu.edu.eg (M.E.S.)
Data Availability Statement
All data are fully available without restriction. All relevant data are within the manuscript.
